首页> 美国卫生研究院文献>The Korean Journal of Internal Medicine >Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

【2h】

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

机译：Alirocumab在韩国高胆固醇血症和高心血管风险患者中的疗效和安全性：ODYSSEY-KT研究的亚分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis.

机译：在韩国人群中尚未完全建立针对Alprocumab的功效和安全性数据，Alirocumab是一种针对原蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）的完全人类单克隆抗体。我们通过预先指定的韩国子分析在ODYSSEY-KT中对它们进行了评估。

著录项

期刊名称 The Korean Journal of Internal Medicine
作者
Chang-Wook Nam; Dong-Soo Kim; Jianyong Li; Marie T. Baccara-Dinet; Ivy Li; Ji-Hyun Kim; Chong-Jin Kim;
展开▼
作者单位

展开▼
年(卷),期 2019(34),6
年度 2019
页码 -1
总页数 14
原文格式 PDF
正文语种
中图分类基础医学;
关键词
PCSK9; Cholesterol; LDL; ODYSSEY; Hypercholesterolemia;

机译：PCSK9;胆固醇;LDL;ODYSSEY;高胆固醇血症;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial [J] . Teramoto Tamio, Kobayashi Masahiko, Tasaki Hiromi, Circulation journal . 2016,第9期

机译：他汀类药物未充分控制的日本杂合子家族性高胆固醇血症或高心血管风险高胆固醇血症患者中Alirocumab的疗效和安全性-ODYSSEY JAPAN随机对照试验
2. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial (vol 80, pg 1980, 2016) [J] . Teramoto Tamio, Kobayashi Masahiko, Tasaki Hiromi, Circulation journal . 2016,第11期

机译：他汀类药物未充分控制的日本杂合子家族性高胆固醇血症或高心血管风险高胆固醇血症患者中Alirocumab的疗效和安全性-ODYSSEY JAPAN随机对照试验（第80卷，1980年，第PG页）
3. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial [J] . Teramoto Tamio, Kobayashi Masahiko, Tasaki Hiromi, Circulation journal . 2016,第9期

机译：Alirocumab在日本杂合子家族高胆固醇血症或高血管血管风险中的疗效和安全性没有充分控制他汀类药物 - 奥德赛日本随机对照试验
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies [O] . Jennifer G. Robinson, Helen M. Colhoun, Harold E. Bays, 2014

机译：Alirocumab作为高胆固醇血症患者（未充分用阿托伐他汀（20或40 mg）或瑞舒伐他汀（10或20 mg）控制的高胆固醇血症患者）的附加治疗的有效性和安全性：ODYSSEY OPTIONS研究的设计和原理
7. Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [O] . Robinson Jennifer G., Colhoun Helen M., Bays Harold E., 2014

机译：Alirocumab辅助治疗对高胆固醇血症高胆固醇血症患者未充分控制的阿托伐他汀（20或40 mg）或瑞舒伐他汀（10或20 mg）的疗效和安全性:: ODYSSEY OPTIONS研究的设计和原理

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

摘要

著录项

相似文献

相关主题

期刊订阅